Sooryanarayana Varambally

List of Publications by Citations

140 papers	27,882 citations	61 h-index	156 g-index
156 ext. papers	32,319 ext. citations	11.8 avg, IF	6.41 L-index

#	Paper	IF	Citations
140	Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. *Science*, **2005**, 310, 644-8	33.3	3022
139	UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. *Neoplasia*, **2017**, 19, 649-658	6.4	2229
138	The polycomb group protein EZH2 is involved in progression of prostate cancer. *Nature*, **2002**, 419, 624-9	50.4	2085
137	Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. *Nature*, **2009**, 457, 910-4	50.4	1636
136	Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. *Neoplasia*, **2007**, 9, 166-80	6.4	1537
135	Delineation of prognostic biomarkers in prostate cancer. *Nature*, **2001**, 412, 822-6	50.4	1402
134	EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2003**, 100, 11606-11	11.5	1295
133	Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. *Science*, **2008**, 322, 1695-9	33.3	888
132	Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. *Nature Medicine* , **2016**, 22, 298-305	50.5	775
131	Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. *Cancer Research*, **2004**, 64, 9209-16	10.1	712
130	Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. *Nature*, **2007**, 448, 595-9	50.4	654
129	An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. *Cancer Cell*, **2010**, 17, 443-54	24.3	640
128	Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. *Cancer Cell*, **2005**, 8, 393-406	24.3	625
127	Role of the TMPRSS2-ERG gene fusion in prostate cancer. *Neoplasia*, **2008**, 10, 177-88	6.4	522
126	Autoantibody signatures in prostate cancer. *New England Journal of Medicine*, **2005**, 353, 1224-35	59.2	521
125	alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. *JAMA - Journal of the American Medical Association*, **2002**, 287, 1662-70	27.4	489
124	Repression of E-cadherin by the polycomb group protein EZH2 in cancer. *Oncogene*, **2008**, 27, 7274-84	9.2	456

123	Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. *Nature Medicine*, **2010**, 16, 793-8	50.5	382
122	Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. *Cancer Cell*, **2011**, 19, 664-78	24.3	342
121	Probabilistic model of the human protein-protein interaction network. *Nature Biotechnology*, **2005**, 23, 951-9	44.5	338
120	Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). *Cancer Research*, **2005**, 65, 3328-35	10.1	313
119	Induced chromosomal proximity and gene fusions in prostate cancer. *Science*, **2009**, 326, 1230	33.3	299
118	Antibody-based detection of ERG rearrangement-positive prostate cancer. *Neoplasia*, **2010**, 12, 590-8	6.4	281
117	JAGGED1 expression is associated with prostate cancer metastasis and recurrence. *Cancer Research* , **2004**, 64, 6854-7	10.1	280
116	A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. *Cancer Research*, **2007**, 67, 10657-63	10.1	270
115	The role of SPINK1 in ETS rearrangement-negative prostate cancers. *Cancer Cell*, **2008**, 13, 519-28	24.3	254
114	Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction. *Nature Immunology*, **2016**, 17, 95-103	19.1	234
113	Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis. *Cancer Research*, **2005**, 65, 11259-64	10.1	221
112	Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. *Cancer Research*, **2008**, 68, 73-80	10.1	212
111	Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer. *Cancer Cell*, **2007**, 12, 419-31	24.3	185
110	Coordinated regulation of polycomb group complexes through microRNAs in cancer. *Cancer Cell*, **2011**, 20, 187-99	24.3	176
109	Nod1 acts as an intracellular receptor to stimulate chemokine production and neutrophil recruitment in vivo. *Journal of Experimental Medicine*, **2006**, 203, 203-13	16.6	173
108	Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 19488-93	11.5	152
107	Pan-cancer molecular subtypes revealed by mass-spectrometry-based proteomic characterization of more than 500 human cancers. *Nature Communications*, **2019**, 10, 5679	17.4	150
106	Overexpression, amplification, and androgen regulation of TPD52 in prostate cancer. *Cancer Research*, **2004**, 64, 3814-22	10.1	136

105	C5a-induced gene expression in human umbilical vein endothelial cells. *American Journal of Pathology*, **2004**, 164, 849-59	5.8	134
104	A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer. *Cancer Research*, **2008**, 68, 7629-37	10.1	127
103	Chemotherapy induces secretion of exosomes loaded with heparanase that degrades extracellular matrix and impacts tumor and host cell behavior. *Matrix Biology*, **2018**, 65, 104-118	11.4	125
102	Changes in differential gene expression because of warm ischemia time of radical prostatectomy specimens. *American Journal of Pathology*, **2002**, 161, 1743-8	5.8	124
101	Therapeutic targeting of SPINK1-positive prostate cancer. *Science Translational Medicine*, **2011**, 3, 72ra17	17.5	120
100	Molecular concepts analysis links tumors, pathways, mechanisms, and drugs. *Neoplasia*, **2007**, 9, 443-54	6.4	118
99	Targeting of microRNA-142-3p in dendritic cells regulates endotoxin-induced mortality. *Blood*, **2011**, 117, 6172-83	2.2	116
98	The role of metastasis-associated protein 1 in prostate cancer progression. *Cancer Research*, **2004**, 64, 825-9	10.1	116
97	AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 10284-9	11.5	111
96	Characterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancer. *Molecular Cell*, **2013**, 49, 80-93	17.6	110
95	alpha-Methylacyl-CoA racemase: expression levels of this novel cancer biomarker depend on tumor differentiation. *American Journal of Pathology*, **2002**, 161, 841-8	5.8	105
94	Natural antibodies sustain differentiation and maturation of human dendritic cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 14210-5	11.5	95
93	The tumor suppressor gene rap1GAP is silenced by miR-101-mediated EZH2 overexpression in invasive squamous cell carcinoma. *Oncogene*, **2011**, 30, 4339-49	9.2	86
92	Genomic and Epigenomic Alterations in Cancer. *American Journal of Pathology*, **2016**, 186, 1724-35	5.8	84
91	Characterization of KRAS rearrangements in metastatic prostate cancer. *Cancer Discovery*, **2011**, 1, 35-43	24.4	83
90	TRIP13 promotes error-prone nonhomologous end joining and induces chemoresistance in head and neck cancer. *Nature Communications*, **2014**, 5, 4527	17.4	81
89	The Polycomb group protein EZH2 impairs DNA repair in breast epithelial cells. *Neoplasia*, **2005**, 7, 1011-9	6.4	79
88	Autoantibody profiles reveal ubiquilin 1 as a humoral immune response target in lung adenocarcinoma. *Cancer Research*, **2007**, 67, 3461-7	10.1	76

87	Molecular cross-talk between the TRAIL and interferon signaling pathways. *Journal of Biological Chemistry*, **2002**, 277, 575-85	5.4	75
86	Golgi protein GOLM1 is a tissue and urine biomarker of prostate cancer. *Neoplasia*, **2008**, 10, 1285-94	6.4	74
85	Defining aggressive prostate cancer using a 12-gene model. *Neoplasia*, **2006**, 8, 59-68	6.4	73
84	ADAM15 disintegrin is associated with aggressive prostate and breast cancer disease. *Neoplasia*, **2006**, 8, 319-29	6.4	73
83	The miR-124-prolyl hydroxylase P4HA1-MMP1 axis plays a critical role in prostate cancer progression. *Oncotarget*, **2014**, 5, 6654-69	3.3	70
82	The neuronal repellent SLIT2 is a target for repression by EZH2 in prostate cancer. *Oncogene*, **2010**, 29, 5370-80	9.2	68
81	An integrative approach to reveal driver gene fusions from paired-end sequencing data in cancer. *Nature Biotechnology*, **2009**, 27, 1005-11	44.5	63
80	Role of epidermal growth factor receptor degradation in gemcitabine-mediated cytotoxicity. *Oncogene*, **2007**, 26, 3431-9	9.2	62
79	RHAMM (CD168) is overexpressed at the protein level and may constitute an immunogenic antigen in advanced prostate cancer disease. *Neoplasia*, **2009**, 11, 956-63	6.4	58
78	Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer. *Cancer Cell*, **2017**, 31, 532-548.e7	24.3	57
77	Inhibition of CCN6 (Wnt-1-induced signaling protein 3) down-regulates E-cadherin in the breast epithelium through induction of snail and ZEB1. *American Journal of Pathology*, **2008**, 172, 893-904	5.8	56
76	Inhibition of histone methylation arrests ongoing graft-versus-host disease in mice by selectively inducing apoptosis of alloreactive effector T cells. *Blood*, **2012**, 119, 1274-82	2.2	54
75	Histone Methyltransferase EZH2: A Therapeutic Target for Ovarian Cancer. *Molecular Cancer Therapeutics*, **2018**, 17, 591-602	6.1	50
74	The kinase activity of the Ser/Thr kinase BUB1 promotes TGF-signaling. *Science Signaling*, **2015**, 8, ra1	8.8	50
73	Role and regulation of coordinately expressed de novo purine biosynthetic enzymes PPAT and PAICS in lung cancer. *Oncotarget*, **2015**, 6, 23445-61	3.3	49
72	Role of transcriptional corepressor CtBP1 in prostate cancer progression. *Neoplasia*, **2012**, 14, 905-14	6.4	49
71	Effect of epidermal growth factor receptor inhibitor class in the treatment of head and neck cancer with concurrent radiochemotherapy in vivo. *Clinical Cancer Research*, **2007**, 13, 2512-8	12.9	47
70	The unfolded protein response modulates toxicity of the expanded glutamine androgen receptor. *Journal of Biological Chemistry*, **2005**, 280, 21264-71	5.4	46

69	Alpha-methylacyl-CoA racemase protein expression is associated with the degree of differentiation in breast cancer using quantitative image analysis. *Cancer Epidemiology Biomarkers and Prevention*, **2005**, 14, 1418-23	4	45
68	UALCAN: An update to the integrated cancer data analysis platform.. *Neoplasia*, **2022**, 25, 18-27	6.4	44
67	MicroRNA-101 regulated transcriptional modulator SUB1 plays a role in prostate cancer. *Oncogene*, **2016**, 35, 6330-6340	9.2	43
66	Selection and cloning of poly(rC)-binding protein 2 and Raf kinase inhibitor protein RNA activators of 2Ţ5Ŧoligoadenylate synthetase from prostate cancer cells. *Nucleic Acids Research*, **2006**, 34, 6684-95	20.1	41
65	TMPRSS2-ERG-mediated feed-forward regulation of wild-type ERG in human prostate cancers. *Cancer Research*, **2011**, 71, 5387-92	10.1	40
64	EZH2-Targeted Therapies in Cancer: Hype or a Reality. *Cancer Research*, **2020**, 80, 5449-5458	10.1	40
63	Inhibition of Hedgehog signaling reprograms the dysfunctional immune microenvironment in breast cancer. *OncoImmunology*, **2019**, 8, 1548241	7.2	39
62	Proteomic interrogation of androgen action in prostate cancer cells reveals roles of aminoacyl tRNA synthetases. *PLoS ONE*, **2009**, 4, e7075	3.7	39
61	Genome-wide DNA methylation encodes cardiac transcriptional reprogramming in human ischemic heart failure. *Laboratory Investigation*, **2019**, 99, 371-386	5.9	38
60	Ferritin Light Chain Confers Protection Against Sepsis-Induced Inflammation and Organ Injury. *Frontiers in Immunology*, **2019**, 10, 131	8.4	33
59	Enhancing the antitumor activity of ErbB blockade with histone deacetylase (HDAC) inhibition. *International Journal of Cancer*, **2006**, 118, 1041-50	7.5	33
58	miR-34a Regulates Expression of the Stathmin-1 Oncoprotein and Prostate Cancer Progression. *Molecular Cancer Research*, **2018**, 16, 1125-1137	6.6	31
57	Natural human polyreactive IgM induce apoptosis of lymphoid cell lines and human peripheral blood mononuclear cells. *International Immunology*, **2004**, 16, 517-24	4.9	31
56	Expression and Role of PAICS, a De Novo Purine Biosynthetic Gene in Prostate Cancer. *Prostate*, **2017**, 77, 10-21	4.2	27
55	Integrative Epigenetic and Gene Expression Analysis of Renal Tumor Progression to Metastasis. *Molecular Cancer Research*, **2019**, 17, 84-96	6.6	26
54	A Role for De Novo Purine Metabolic Enzyme PAICS in Bladder Cancer Progression. *Neoplasia*, **2018**, 20, 894-904	6.4	25
53	Ataxia telangiectasia mutated down-regulates phospho-extracellular signal-regulated kinase 1/2 via activation of MKP-1 in response to radiation. *Cancer Research*, **2006**, 66, 11554-9	10.1	24
52	Differential proteomic alterations between localised and metastatic prostate cancer. *British Journal of Cancer*, **2006**, 95, 425-30	8.7	23

51	Dysregulation of de novo nucleotide biosynthetic pathway enzymes in cancer and targeting opportunities. *Cancer Letters*, **2020**, 470, 134-140	9.9	23
50	Large-scale profiling of serum metabolites in African American and European American patients with bladder cancer reveals metabolic pathways associated with patient survival. *Cancer*, **2019**, 125, 921-932	6.4	22
49	MTHFD1L, A Folate Cycle Enzyme, Is Involved in Progression of Colorectal Cancer. *Translational Oncology*, **2019**, 12, 1461-1467	4.9	19
48	Gene Expression Profiling of Advanced Penile Squamous Cell Carcinoma Receiving Cisplatin-based Chemotherapy Improves Prognostication and Identifies Potential Therapeutic Targets. *European Urology Focus*, **2018**, 4, 733-736	5.1	16
47	Re: Florian Jentzmik, Carsten Stephan, Kurt Miller, et al. Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. Eur Urol 2010;58:12-8. *European Urology*, **2010**, 58, e29-30; author reply e31-2	10.2	16
46	PAICS, a Purine Nucleotide Metabolic Enzyme, is Involved in Tumor Growth and the Metastasis of Colorectal Cancer. *Cancers*, **2020**, 12,	6.6	15
45	Prostate Cancer Imaging and Biomarkers Guiding Safe Selection of Active Surveillance. *Frontiers in Oncology*, **2017**, 7, 256	5.3	15
44	Molecular Correlates of Metastasis by Systematic Pan-Cancer Analysis Across The Cancer Genome Atlas. *Molecular Cancer Research*, **2019**, 17, 476-487	6.6	15
43	The enzymatic activity of apoptosis-inducing factor supports energy metabolism benefiting the growth and invasiveness of advanced prostate cancer cells. *Journal of Biological Chemistry*, **2012**, 287, 43862-75	5.4	14
42	Amplified centrosomes may underlie aggressive disease course in pancreatic ductal adenocarcinoma. *Cell Cycle*, **2015**, 14, 2798-809	4.7	13
41	Targeting P4HA1 with a Small Molecule Inhibitor in a Colorectal Cancer PDX Model. *Translational Oncology*, **2020**, 13, 100754	4.9	13
40	Wnt receptor Frizzled 8 is a target of ERG in prostate cancer. *Prostate*, **2018**, 78, 1311-1320	4.2	13
39	TRIP13 promotes metastasis of colorectal cancer regardless of p53 and microsatellite instability status. *Molecular Oncology*, **2020**, 14, 3007-3029	7.9	13
38	Amplified centrosomes and mitotic index display poor concordance between patient tumors and cultured cancer cells. *Scientific Reports*, **2017**, 7, 43984	4.9	12
37	Role of dutasteride in pre-clinical ETS fusion-positive prostate cancer models. *Prostate*, **2012**, 72, 1542-9	4.2	12
36	PRDM16 suppresses HIF-targeted gene expression in kidney cancer. *Journal of Experimental Medicine*, **2020**, 217,	16.6	11
35	14-3-3 proteins protect AMPK-phosphorylated ten-eleven translocation-2 (TET2) from PP2A-mediated dephosphorylation. *Journal of Biological Chemistry*, **2020**, 295, 1754-1766	5.4	10
34	PGC1 suppresses kidney cancer progression by inhibiting collagen-induced SNAIL expression. *Matrix Biology*, **2020**, 89, 43-58	11.4	10

33	Pseudogene Associated Recurrent Gene Fusion in Prostate Cancer. *Neoplasia*, **2019**, 21, 989-1002	6.4	9
32	Therapeutically actionable PAK4 is amplified, overexpressed, and involved in bladder cancer progression. *Oncogene*, **2020**, 39, 4077-4091	9.2	8
31	A systems approach to model metastatic progression. *Cancer Research*, **2006**, 66, 5537-9	10.1	8
30	Mass-spectrometry-based proteomic correlates of grade and stage reveal pathways and kinases associated with aggressive human cancers. *Oncogene*, **2021**, 40, 2081-2095	9.2	8
29	PAICS, a De Novo Purine Biosynthetic Enzyme, Is Overexpressed in Pancreatic Cancer and Is Involved in Its Progression. *Translational Oncology*, **2020**, 13, 100776	4.9	7
28	MicroRNA-mediated inflammation and coagulation effects in rats exposed to an inhaled analog of sulfur mustard. *Annals of the New York Academy of Sciences*, **2020**, 1479, 148-158	6.5	7
27	Expression and Role of Methylenetetrahydrofolate Dehydrogenase 1 Like (MTHFD1L) in Bladder Cancer. *Translational Oncology*, **2019**, 12, 1416-1424	4.9	7
26	The combined survival effect of codon 72 polymorphisms and p53 somatic mutations in breast cancer depends on race and molecular subtype. *PLoS ONE*, **2019**, 14, e0211734	3.7	6
25	Comparative transcriptome analyses reveal genes associated with SARS-CoV-2 infection of human lung epithelial cells. *Scientific Reports*, **2021**, 11, 16212	4.9	6
24	Loss of RUNX3 expression is an independent adverse prognostic factor in diffuse large B-cell lymphoma. *Leukemia and Lymphoma*, **2017**, 58, 179-184	1.9	5
23	Tomlins et al. reply. *Nature*, **2009**, 457, E2-E3	50.4	5
22	Characterization of glycine-N-acyltransferase like 1 (GLYATL1) in prostate cancer. *Prostate*, **2019**, 79, 1629-1639	4.2	4
21	Targeting the link between late pregnancy and breast cancer. *ELife*, **2013**, 2, e01926	8.9	4
20	Fermentable fiber-induced hepatocellular carcinoma in mice recapitulates gene signatures found in human liver cancer. *PLoS ONE*, **2020**, 15, e0234726	3.7	3
19	Subcellular localization of EZH2 phosphorylated at T367 stratifies metaplastic breast carcinoma subtypes. *Breast Cancer*, **2021**, 28, 496-505	3.4	3
18	Comparative analysis of triple-negative breast cancer transcriptomics of Kenyan, African American and Caucasian Women. *Translational Oncology*, **2021**, 14, 101086	4.9	3
17	Proteogenomic characterization of 2002 human cancers reveals pan-cancer molecular subtypes and associated pathways.. *Nature Communications*, **2022**, 13, 2669	17.4	3
16	Expression of MHC class I polypeptide-related sequence A (MICA) in colorectal cancer. *Frontiers in Bioscience*, **2021**, 26, 765-776		2

List of Publications

15	Comparative transcriptome analyses reveal genes associated with SARS-CoV-2 infection of human lung epithelial cells		2
14	NAB2-STAT6 Gene Fusions to Evaluate Primary/Metastasis of Hemangiopericytoma/Solitary Fibrous Tumors. *American Journal of Clinical Pathology*, **2021**, 156, 906-912	1.9	2
13	Collagen modifying enzyme P4HA1 is overexpressed and plays a role in lung adenocarcinoma. *Translational Oncology*, **2021**, 14, 101128	4.9	2
12	Prostate Cancer: An Update on Molecular Pathology with Clinical Implications. *European Urology Supplements*, **2017**, 16, 253-271	0.9	1
11	Fermentable fibers induce rapid macro- and micronutrient depletion in Toll-like receptor 5-deficient mice. *American Journal of Physiology - Renal Physiology*, **2020**, 318, G955-G965	5.1	1
10	Global molecular alterations involving recurrence or progression of pediatric brain tumors. *Neoplasia*, **2021**, 24, 22-33	6.4	1
9	The TGF-β/HDAC7 axis suppresses TCA cycle metabolism in renal cancer. *JCI Insight*, **2021**, 6,	9.9	1
8	ARID1A-mutant and deficient bladder cancer is sensitive to EZH2 pharmacologic inhibition		1
7	Meta-Analysis of Robustness of COVID-19 Diagnostic Kits During Early Pandemic **2021**,		1
6	MS4A3 Promotes Differentiation in Chronic Myeloid Leukemia By Enhancing Common γChain Cytokine Receptor Endocytosis. *Blood*, **2021**, 138, 59-59	2.2	
5	EZH2 Upregulation Is Associated with Unfavorable Prognosis in Diffuse Large B-Cell Lymphoma through Potential RUNX3 Downregulation. *Blood*, **2016**, 128, 5301-5301	2.2	
4	Increased Expression of EZH2 Is Associated with Inferior Survival in Primary Central Nervous System Diffuse Large B-Cell Lymphoma. *Blood*, **2016**, 128, 4216-4216	2.2	
3	Inhibition of Histone Methylation Arrests Ongoing Graft-Versus-Host Diseases in Mice by Selectively Inducing Apoptosis of Alloreactive Effector T Cells. *Blood*, **2011**, 118, 820-820	2.2	
2	Meta-analysis of the robustness of COVID-19 diagnostic kit performance during the early pandemic.. *BMJ Open*, **2022**, 12, e053912	3	
1	Distinct Gene Expression Profiles of Matched Primary and Metastatic Triple-Negative Breast Cancers. *Cancers*, **2022**, 14, 2447	6.6	